Bristol Myers Squibb holds a patent related to dasatinib, a tyrosine kinase inhibitor used in cancer treatment, filed in 2000. This patent pertains to the compound itself and its use. The patent details are available through resources like DrugPatentWatch.com [1].
When does the patent for dasatinib expire?
The primary patent for dasatinib, often referred to as the "compound patent," was filed in 2000. Exclusivity for this patent typically extends for 20 years from the filing date, placing its expiry around 2020. However, patent terms can be extended due to factors like patent term extensions (PTE) granted by regulatory agencies for market exclusivity lost during the patent review process [1][2]. Supplementary protection certificates (SPCs) in Europe can also extend patent life.
Can generic versions of dasatinib be produced?
Once patents expire and any applicable exclusivity periods like PTE or SPCs have ended, generic versions of dasatinib can be manufactured and marketed. The availability of generic competition significantly impacts drug pricing and accessibility. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), must approve generic versions, ensuring they are bioequivalent to the branded drug [1][3].
What is the status of other patents covering dasatinib?
Beyond the initial compound patent, there may be other patents covering specific formulations, manufacturing processes, or methods of use for dasatinib. These secondary patents can influence the timeline for generic entry. Challenges to these patents through litigation can also alter their validity or duration, potentially opening doors for generic competition sooner than anticipated [1]. DrugPatentWatch.com tracks these various patent filings and their associated legal statuses.
What is dasatinib used for?
Dasatinib is a targeted therapy approved for treating certain types of leukemia, specifically Philadelphia chromosome-positive chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [4]. It works by inhibiting specific tyrosine kinases that drive the growth of cancer cells.
Who manufactures dasatinib?
Bristol Myers Squibb is the original manufacturer of dasatinib, marketed under the brand name Sprycel [4]. Following patent expiries, other pharmaceutical companies may produce and market generic versions of the drug.
What are the risks associated with dasatinib treatment?
Like all medications, dasatinib carries potential risks and side effects. Common side effects can include nausea, diarrhea, rash, headache, fatigue, and fluid retention. More serious side effects, though less common, can involve bleeding events, heart problems (such as QT prolongation and heart failure), lung issues, and myelosuppression (low blood cell counts) [4]. Patients should discuss potential risks and benefits with their healthcare provider.
How does dasatinib compare to other leukemia treatments?
Dasatinib is one of several tyrosine kinase inhibitors (TKIs) available for treating CML and Ph+ ALL. It is often compared to other TKIs like imatinib (Gleevec), nilotinib (Tasigna), and bosutinib (Bosulif). The choice of TKI depends on factors such as the patient's specific mutation profile, disease phase, previous treatment history, and tolerability of side effects [5].
What is the cost of dasatinib?
The cost of dasatinib can be substantial, particularly for the branded version. Generic versions, once available, typically lead to a significant reduction in price. Patient assistance programs and insurance coverage often play a role in managing out-of-pocket expenses for patients [1].
---
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/drugs/patent-certification/patent-exclusivity
[3] https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas-generics
[4] https://www.sprycel.com/
[5] https://www.lls.org/treatment/types-of-leukemia/chronic-myeloid-leukemia-cml/treatment-options